Patents Examined by Kate Poliakova
  • Compositions and methods for treatment of ovarian cancer
    Patent number: 9487781
    Abstract: The disclosure provides compositions and methods for treating an ovarian cancer in a subject. More specifically, the disclosure provides microRNA (miRNA) inhibitor molecules that target to different miRNAs for treating different types of ovarian cancers in a subject. Furthermore, different modifications of miRNA inhibitor molecules as well as different derivatives of miRNA inhibitor molecules are also described.
    Type: Grant
    Filed: October 3, 2014
    Date of Patent: November 8, 2016
    Assignee: Rosetta Genomics Ltd.
    Inventor: Noga Yerushalmi
  • Methods and compositions using miR-3151 in the diagnosis and treatment of cancer
    Patent number: 9469852
    Abstract: Compositions comprising therapeutic oligonucleotide miR-3151 compounds that target the expression of genes associated with tumorigenesis or cell transformation are provided.
    Type: Grant
    Filed: April 24, 2015
    Date of Patent: October 18, 2016
    Assignee: The Ohio State University
    Inventors: Albert de la Chapelle, Ann-Kathrin Eisfeld
  • Methods of inhibiting Alu RNA and therapeutic uses thereof
    Patent number: 9464289
    Abstract: The presently-disclosed subject matter includes methods of identifying an Alu RNA inhibitor, and methods and compositions for inhibiting Alu RNA. Methods and compositions can be used for the treatment of geographic atrophy and other conditions of interest.
    Type: Grant
    Filed: July 3, 2014
    Date of Patent: October 11, 2016
    Assignee: University of Kentucky Research Foundation
    Inventor: Jayakrishna Ambati
  • Methods and compositions for the specific inhibition of alpha-1 antitrypsin by double-stranded RNA
    Patent number: 9458457
    Abstract: This invention relates to compounds, compositions, and methods useful for reducing ?-1 antitrypsin target RNA and protein levels via use of dsRNAs, e.g., Dicer substrate siRNA (DsiRNA) agents.
    Type: Grant
    Filed: July 3, 2014
    Date of Patent: October 4, 2016
    Assignee: Dicerna Pharmaceuticals, Inc.
    Inventors: Bob D. Brown, Henryk T. Dudek
  • Long noncoding RNAS and cell reprogramming and differentiation
    Patent number: 9441224
    Abstract: Long noncoding RNAs (lncRNAs) are identified that enhance pluripotency reprogramming of somatic cells as well as differentiation of pluripotent cells. Induced pluripotent stem (iPS) cell generation from somatic cells leads to the upregulation and downregulation of identified lncRNAs. The modulation of these lncRNAs are capable of enhancing pluripotency of somatic cells as well as enhancing differentiation of a pluripotent cell.
    Type: Grant
    Filed: June 27, 2014
    Date of Patent: September 13, 2016
    Assignee: CALIFORNIA INSTITUTE OF TECHNOLOGY
    Inventors: Daniel H. Kim, Barbara J. Wold
  • DNA polymerases with improved activity
    Patent number: 9441269
    Abstract: Disclosed are DNA polymerases having increased reverse transcriptase efficiency relative to a corresponding, unmodified polymerase. The polymerases are useful in a variety of disclosed primer extension methods. Also disclosed are related compositions, including recombinant nucleic acids, vectors, and host cells, which are useful, e.g., for production of the DNA polymerases.
    Type: Grant
    Filed: December 19, 2014
    Date of Patent: September 13, 2016
    Assignee: Roche Molecular Systems, Inc.
    Inventors: Keith Bauer, Thomas W. Myers, Shawn Suko
  • Conjugates of small-interfering nucleic acids
    Patent number: 9433684
    Abstract: The present invention relates to conjugates of small-interfering nucleic acids (siNA). Compositions of siNA suited for administration to a patient are described. Methods for delivering the compositions are also described.
    Type: Grant
    Filed: August 19, 2009
    Date of Patent: September 6, 2016
    Assignee: Nektar Therapeutics
    Inventors: Samuel P. McManus, Timothy A. Riley, Sean M. Culbertson, Antoni Kozlowski, Dennis G. Fry, Xuejun Yuan, Dawei Sheng, Vidula R. Dixit
  • Methods and compositions for the specific inhibition of beta-catenin by double-stranded RNA
    Patent number: 9428752
    Abstract: This invention relates to compounds, compositions, and methods useful for reducing ?-catenin target RNA and protein levels via use of dsRNAs, e.g., Dicer substrate siRNA (DsiRNA) agents.
    Type: Grant
    Filed: October 28, 2015
    Date of Patent: August 30, 2016
    Assignee: Dicerna Pharmaceuticals, Inc.
    Inventors: Bob D. Brown, Henryk T. Dudek
  • DNA aptamer specifically binding to EN2 (engrailed-2) and use thereof
    Patent number: 9429575
    Abstract: The present invention relates to a DNA aptamer specifically binding to EN2 (Engrailed-2), a biosensor for diagnosing prostate cancer having the same, and a method of diagnosing prostate cancer. A strong binding force and excellent specificity of the DNA aptamer of the present invention and the biosensor using the same with respect to EN2 proteins were identified. A detection specificity problem of a prostate-specific antigen (PSA) test used for prostate cancer diagnosis of the related art was addressed. Therefore, the present invention is expected to be beneficially used for early diagnosis of prostate cancer more effectively and increase diagnostic accuracy.
    Type: Grant
    Filed: November 5, 2015
    Date of Patent: August 30, 2016
    Assignee: Postech Academy-Industry Foundation
    Inventors: Changill Ban, Yoon-Keun Kim, Hunho Jo, Seonghwan Lee, Hyung Jun Youn
  • Polycomb-associated non-coding RNAs
    Patent number: 9328346
    Abstract: This invention relates to long non-coding RNAs (lncRNAs), libraries of those ncRNAs that bind chromatin modifiers, such as Polycomb Repressive Complex 2, inhibitory nucleic acids and methods and compositions for targeting lncRNAs.
    Type: Grant
    Filed: November 12, 2011
    Date of Patent: May 3, 2016
    Assignee: The General Hospital Corporation
    Inventors: Jeannie T. Lee, Jing Zhao, Kavitha Sarma, Mark Borowsky, Toshiro Kendrick Ohsumi
  • Polyplexes of hydrophobically-modified siRNA for delivery of siRNA
    Patent number: 9320814
    Abstract: The present invention provides compositions and methods for delivering nucleic acid molecules to a cell.
    Type: Grant
    Filed: November 1, 2012
    Date of Patent: April 26, 2016
    Assignee: Board of Regents of the University of Nebraska
    Inventor: Joseph A. Vetro
  • MicroRNA compounds and methods for modulating miR-122
    Patent number: 9309513
    Abstract: Described herein are compositions and methods for the inhibition of miR-122 activity. The compositions have certain nucleoside modifications that yield potent inhibitors of miR-122 activity. The compounds may comprise conjugates to facilitate delivery to the liver. The compositions may be administered to subjects infected with hepatitis C virus, as a treatment for hepatitis C virus and related conditions.
    Type: Grant
    Filed: April 30, 2014
    Date of Patent: April 12, 2016
    Assignee: Regulus Therapeutics Inc.
    Inventors: Balkrishen Bhat, Daniel Hogan
  • Method and compositions comprising small RNA agonist and antagonists to modulate inflammation
    Patent number: 9303258
    Abstract: The disclosure provides methods and compositions for modulating inflammation.
    Type: Grant
    Filed: April 5, 2012
    Date of Patent: April 5, 2016
    Assignee: The Regents of the University of California
    Inventors: Richard L. Gallo, Jamie Bernard
  • Small molecule conjugates for intracellular delivery of biologically active compounds
    Patent number: 9301990
    Abstract: The invention provides novel compounds and conjugates of these compounds useful for the delivery of biologically active substances. Further novel design criteria for chemically stabilized siRNA particular useful when covalently attached to a delivery polymer to achieve in vivo mRNA knock down are disclosed therein.
    Type: Grant
    Filed: June 13, 2013
    Date of Patent: April 5, 2016
    Assignee: HOFFMANN-LA ROCHE, INC.
    Inventors: Philipp Hadwiger, Torsten Hoffmann, Kerstin Jahn-Hofmann, Eric A. Kitas, David L. Lewis, Peter Mohr, Hans Martin Mueller, Guenther Ott, Ingo Roehl, David B. Rozema
  • Archease as RNA ligaes complex member
    Patent number: 9296994
    Abstract: The present invention relates to the use of Archease proteins as RNA ligase enhancer, methods of ligating RNA molecules, kits for these methods and uses and transgenic cells.
    Type: Grant
    Filed: April 23, 2013
    Date of Patent: March 29, 2016
    Assignee: IMBA-INSTITUT FÜR MOLEKULARE BIOTECHNOLOGIE GMBH
    Inventors: Johannes Popow, Javier Martinez, Anne Nielsen, Alexander Schleiffer, Theresa Henkel
  • Aptazyme capable of selective silencing of target miRNA by releasing an antisense sequence in hepatitis C virus-infected cells and use thereof
    Patent number: 9284555
    Abstract: The present invention relates to an aptazyme comprising an aptamer for hepatitis C virus (HCV) RNA-encoding component; a hammerhead ribozyme comprising an antisense sequence to microRNA at the site released by self-cleavage; and a communication module sequence that connects the aptamer and hammerhead ribozyme and triggers a self-cleavage activity of the hammerhead ribozyme upon binding of the aptamer with the HCV RNA-encoding component. The present aptazyme inhibits microRNA activity specifically in HCV proliferating cells and thus a composition of the present invention comprising the aptazyme can be effectively used for treatment of HCV-related diseases.
    Type: Grant
    Filed: September 16, 2011
    Date of Patent: March 15, 2016
    Assignee: Industry-Academic Cooperation Foundation Dankook University
    Inventors: Seong-Wook Lee, Chang-Ho Lee
  • MicroRNA compounds and methods for modulating miR-21 activity
    Patent number: 9267137
    Abstract: Described herein are compositions and methods for the inhibition of miR-21 activity. The compositions have certain nucleoside modification patterns that yield potent inhibitors of miR-21 activity. The compositions may be used to inhibit miR-21, and also to treat diseases associated with abnormal expression of miR-21, such as fibrosis and cancer.
    Type: Grant
    Filed: January 15, 2015
    Date of Patent: February 23, 2016
    Assignee: Regulus Therapeutics Inc.
    Inventors: Balkrishen Bhat, Eric Marcusson
  • Methods and compositions for treating cancer
    Patent number: 9249466
    Abstract: We describe a method of determining whether a cancer cell is likely to be resistant to treatment by an mTOR inhibitor. The method may comprise detecting PPP2R2B (GenBank Accession Number: NM_18167) in or of the cell. It may, alternatively, or in addition, comprise detecting PDK1 (GenBank Accession Number: NM_002613), in or of the cell. The method may comprise detecting methylation of the PPP2R2B promoter in or of the cell. It may comprise detecting the expression and/or activity of PPP2R2B in or of the cell. It may comprise detecting PDK1 mediated Myc phosphorylation activity.
    Type: Grant
    Filed: January 10, 2011
    Date of Patent: February 2, 2016
    Assignee: Agency for Science, Technology and Research
    Inventors: Qiang Yu, Jing Tan
  • Methods and compositions for the specific inhibition of beta-catenin by double stranded RNA
    Patent number: 9243244
    Abstract: This invention relates to compounds, compositions, and methods useful for reducing ?-catenin target RNA and protein levels via use of dsRNAs, e.g., Dicer substrate siRNA (DsiRNA) agents.
    Type: Grant
    Filed: June 10, 2014
    Date of Patent: January 26, 2016
    Assignee: Dicerna Pharmaceuticals, Inc.
    Inventors: Bob D. Brown, Henryk T. Dudek
  • dsRNA endoribonucleases
    Patent number: 9238805
    Abstract: The invention relates to a new double-stranded RNA endoribonuclease, its derivative and/or variant, which has a loop locating in and interacting with the major groove of the double-stranded RNA, exhibiting sequence specific properties in the double-stranded RNA cleavage.
    Type: Grant
    Filed: November 25, 2013
    Date of Patent: January 19, 2016
    Assignee: Miedzynarodowy Instytut Biologii Molekulamej I Komorkowej
    Inventors: Janusz Marek Bujnicki, Krzysztof Jerzy Skowronek, Dariusz Pianka, Agata Agnieszka Sulej